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Endothelial Dysfunction and Inﬂammation: Band Master of the Orchestra of
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Background: Slow ﬂow of contrast without signiﬁcant lesion in coronary arteries can
manifest up to life threateningarrhythmiaand suddendeath.But, its responsiblemechanism
is still unknown. We here want to ﬁnd the most inﬂuential mechanism of slow coronary
ﬂow by analyzing previously proposed theories in a single randomized controlled study.
Methods: Among the approximately 3200 Acute Coronary Syndrome or Unstable
Angina patients who had consecutively done coronary angiogram from 15th October,
2012 to 15thApril, 2013, 100 patients (5810 years; 45male)with neither slow coronary
ﬂow nor signiﬁcant lesion were randomized as Control group and another 100 patients
(5710 years; 81male) were also randomized from212 patients whowere found as slow
coronary ﬂow with normal angiographic ﬁnding as Slow Coronary Flow (SCF) group.
Tortuosity status (whenever there was less than 125 degree angled three or more turns in
slow coronary ﬂow affected artery or two or more normal coronary arteries), de-
mographic parameters and investigations including cardiac enzymes, lipid proﬁles,
platelet and plaque parameters, Viscosity parameters, Echocardiographic parameters,
Inﬂammatory parameters andUricAcidwere recorded and comparedwithin two groups.Figure 1. Study Design Flow ChartResults: Patient gender, High Density Lipoprotein, Hemoglobin, Hematocrit and Uric
Acid had strongest strength of correlation (all p¼0.000 and r>0.31) with SCF group
while Tortuosity was weakly correlated with SCF group (p¼0.002, r¼0.213).
Moreover, only Uric Acid (p¼0.000, CI¼2.244-13.642) and Tortuosity (p¼0.000,
CI¼2.264-14.142) were left as top independent determinant factors for Slow Coronary
Flow after multivariable logistic regression. After ROC curve analysis Uric Acid got
the highest Area Under Curve (AUC¼0.720) with the best cut off point of 286 mmol/L
(Sensitivity¼69%, Speciﬁcity¼69%) followed by Tortuosity. Uric Acid was further
correlated with not only mean TIMI frame count (p¼0.000, r¼0.291) but also number
of affected artery (p¼0.000, r¼0.268).
Conclusion: Uric Acid was found as the most determinant factor of slow coronary ﬂow
followed byTortuosity in our study. Uric Acid also plays a role in both inﬂammation and
endothelial dysfunction. Therefore, Inﬂammation and Endothelial Dysfunction may be
the most inﬂuential mechanism of slow coronary ﬂow phenomenon.S40 JACC Vol 63/12/Suppl S j April 22–25, 2014 j TCTAP Abstracts/PO
Figure 2. Possible Mechanism of Slow Coronary Flow Phenomenon Based
On Endothelial Dysfunction And InﬂammationAdjunctive Procedures: Thrombectomy,
Plaque Modiﬁcation, Others
(TCTAP A-140 to TCTAP A-142)
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Background: The study of effectiveness and safety of manual vacuum thrombex-
traction (MVT) from the IRA in STEMI patients after pre-hospital systemic TLT.
Methods: 242 patients with STEMI after pre-hospital TLT with signs of thrombus
(TTG>1) were divided into 2 groups: in Group (n¼121) standard percutaneous cor-
onary interventions (PCI) were complemented by MVT; in Group 2 (n¼121) only
standard PCI were performed. Baseline clinical, history and coronary angiographic
data were similar for both groups. The average time interval between the onset of
angina pain and the PCI was 5,8 hours. Vast majority of patients from both groups
(>75%) had blood ﬂow in the IRA TIMI-3, with MBG -3 in 61.9% and 48.7% in
both groups, respectively. LV EF was 48.6+4.5% in Gr. 1 and 49.7+5.6% in Gr. 2
(p>9.05). Complete ST resolution was seen in 54.6% and 44.6% of cases, respec-
tively. Hospital mortality was 0,8% and 1,6%, MACE occurred in 1,6% and 2,5% of
cases, respectively (p>0,05).
Results:Mid-term (7,8  1,2 months) mortality in Gr. 1 was 1,6%, and in Gr. 2 2,5%
(p>0,05). No cases of IRA occlusion were seen. In-stent stenosis occurred in 14,8%
of cases in Gr. 1 and in 20,6% in Gr. 2. Signiﬁcant increase of LV EF was seen in both
groups - 54.9  5.5% and 54.3  5.2%, respectively.
Conclusion: Vacuum thrombextraction is safe and does not increase total duration of
myocardial ischemia and the rate of MACE and allows to evacuate thrombotic mass
from the IRA. The combination of this method with interventional procedures permits
to achieve fuller restoration of the blood ﬂow in the microcirculatory bed of the IRA in
STEMI patients after pre-hospital systemic TLT.
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Background: The study of cardioprotective action of intracoronary metabolic cyto-
protector Mexicor (methylethylpiridinol succinate), after recanalization of IRA in
STEMI patients.
Methods: 253 patients (average age - 56  7 years) with acute occlusion of the
proximal or middle segment of the LAD and absent antegrade blood ﬂow (TIMI 0)
underwent successful recanalization of IRA within the ﬁrst 6 hours after the onset of
AMI. Prior to angiography, all patients were randomized into 2 groups. Patients from
Group I (n¼126) received intracoronary Mexicor (0,2 g). Patients from Group II
(control, n¼127) did not receive intracoronary cytoprotector. Baseline clinical, his-
torical and angiographic data were not signiﬁcantly different in the studied groups.
Intracoronary administration of a special solution containing the diluted agent was
performed through a special microcatheter during 10 min. simultaneously with
myocardial reperfusion. Blood samples for markers of cardiomyocytes injury (Troponin
I, myoglobin) were taken during recanalization of IRA, in 12 and 24 hours after the
procedure. On day 10 of the disease all patients underwent control ventriculography, and
also were recommended to have in-hospital control examination in 6 months.
Results: In-hospital course of the disease was rather uneventful, 1 patient (0,8%) died
in Gr. I and 3 (2,3%) – in Gr. II. Average values of Troponin I at 12 hours after the
procedure in Grs. I and II were 311  47 and 632  39 ng/ml, respectively (p<0,05).
In the long-term after the procedure, in average – in 6,8  0,7 months, the survival in
Gr. I was 96,8%, in Gr. II - 87,6% (p>0,05). Baseline clinical indices in both groups
were not signiﬁcantly different. The increase of LV EF in Grs. I and II was 9,2  5,1%
and 4,1  8,2%, respectively (p<0,05). We also noted a signiﬁcantly better dynamics
of contractility on infarct-related segments of the LV in Gr.I in comparison with Gr. II
(p<0,05)
Conclusion: Our study suggests that intracoronary administration of metabolic
cytoprotector Mexicor limits reperfusion injury of the myocardium and contributes to
the preservation of structural and functional integrity of cardiomyocytes
after antegrade blood ﬂow restoration in IRA within the ﬁrst hours after the onset of
AMI.STER/Adjunctive Procedures: Thrombectomy, Plaque Modiﬁcation, Others
